MESOBLAST MODIFIES ADR RATIO TO 10:1, CONSOLIDATING SHARES
Ticker: MEOBF · Form: 6-K · Filed: Jan 5, 2024 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Jan 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: ADR-ratio-change, corporate-action, consolidation
TL;DR
**Mesoblast is consolidating its ADRs 1:2, changing the ratio from 5:1 to 10:1.**
AI Summary
Mesoblast Limited, an Australian biotech company, announced on January 5, 2024, a change to its American Depositary Receipt (ADR) program ratio. The ratio will shift from 5 ordinary shares per 1 ADR to 10 ordinary shares per 1 ADR, effectively consolidating ADRs on a 1:2 basis. This means for every two ADRs an investor currently holds, they will now hold one, potentially impacting the ADR's trading price and liquidity on Nasdaq.
Why It Matters
This ADR ratio change could increase the per-ADR trading price, potentially making the stock more attractive to institutional investors and improving market perception, but it also means fewer ADRs are outstanding.
Risk Assessment
Risk Level: low — This is an administrative change to the ADR program and does not reflect a change in the company's underlying value or operations.
Analyst Insight
Investors should be aware that their ADR holdings will be consolidated 1:2, meaning their number of ADRs will halve, but the value per ADR should approximately double, maintaining their total investment value. No immediate action is required, but understanding the change prevents confusion.
Key Numbers
- 5:1 — Previous ADR ratio (5 ordinary shares represented 1 ADR)
- 10:1 — New ADR ratio (10 ordinary shares will represent 1 ADR)
- 1:2 — ADR consolidation basis (for every two existing ADRs, investors will now hold one)
- January 5, 2024 — Date of notice (when Mesoblast provided the notice of ADR ratio change)
Key Players & Entities
- Mesoblast Limited (company) — the registrant modifying its ADR program
- Silviu Itescu (person) — Chief Executive Officer and Executive Director of Mesoblast Limited
- Niva Sivakumar (person) — Company Secretary of Mesoblast Limited
- Nasdaq (company) — the exchange where Mesoblast's ADRs trade
Forward-Looking Statements
- The per-ADR trading price will approximately double following the ratio change. (Mesoblast Limited ADRs) — high confidence, target: Shortly after implementation
- The total market capitalization of Mesoblast will remain unchanged due to this administrative action. (Mesoblast Limited) — high confidence, target: Ongoing
FAQ
What is the primary purpose of Mesoblast's 6-K filing dated January 5, 2024?
The primary purpose of Mesoblast's 6-K filing dated January 5, 2024, is to announce a modification to its American Depositary Receipt (ADR) program ratio.
What was the previous ratio of ordinary shares to ADRs for Mesoblast?
The previous ratio for Mesoblast's ADR program was 5 ordinary shares representing 1 ADR (a 5:1 ratio).
What is the new ratio of ordinary shares to ADRs that Mesoblast is implementing?
Mesoblast is implementing a new ratio of 10 ordinary shares representing 1 ADR (a 10:1 ratio).
How will this ratio change affect the number of ADRs an investor holds?
This ratio change will result in a consolidation of ADRs on a 1:2 basis, meaning an investor will hold half the number of ADRs they previously held for the same underlying ordinary shares.
Who signed the 6-K report on behalf of Mesoblast Limited?
The 6-K report was signed by Niva Sivakumar, Company Secretary, on behalf of Mesoblast Limited.
Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 16.9 · Accepted 2024-01-04 21:38:49
Filing Documents
- a2024-01x05adrratiochange.htm (6-K) — 19KB
- exhibit991adrratiochange.htm (EX-99.1) — 7KB
- exhibit991adrratiochange001.jpg (GRAPHIC) — 306KB
- exhibit991adrratiochange002.jpg (GRAPHIC) — 84KB
- 0001345099-24-000007.txt ( ) — 564KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Niva Sivakumar Niva Sivakumar Company Secretary Dated January 5, 2024 INDEX TO EXHIBITS Item 99.1 Notice dated January 5, 2024.